Drug intelligence / Profile preview

Alocyte (The Center for Regenerative Medicine)

Development stage: Unknown
Lead developer: The Center for Regenerative Medicine
Modality: Cell Therapies
Administration: Intraarticular

Overview

Alocyte is an investigational biologic therapy composed of cord blood plasma and mononuclear cells (MNCs). Developed by Alimorad Farshchian, it is being evaluated for the treatment of facetogenic back pain. The product is administered via intra-articular facet injection and is intended to reduce local inflammation and alleviate pain. As a cell-based therapy combined with plasma, it likely leverages a variety of growth factors and cytokines to promote a regenerative environment within the facet joint.

Brand names: Alocyte
Other names: cord blood plasma plus mononucleic cells

Beyond the preview

Go deeper on Alocyte (The Center for Regenerative Medicine).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alocyte (The Center for Regenerative Medicine).

Explore the full profile